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Abstract
Aiming to reduce the potential in vivo hepato-and neph‐
rotoxicity of Ag/Au bimetallic nanoparticles (NPs) stabi‐
lized by sodium dodecyl sulphate (SDS), an approach
involving a simultaneous reduction of silver nitrate and
tetrachlorauratic acid using tryptophan (Trp) as a reduc‐
ing/stabilizing agent was applied during NP synthesis. The
obtained Ag/Au/Trp NPs (5-15 nm sized) were able to form
stable aggregates with an average size of 370-450 nm and
were potentially less toxic than Ag/Au/SDS in relation to a
mouse model system based on clinical biochemical param‐
eters and oxidative damage product estimation.
Ag/Au/Trp NPs were shown to exhibit anticancer activity
in relation to a Lewis lung carcinoma model. The data
generated from the present study support the fact that the
use of tryptophan in NP synthesis is effective in attenuating
the potential hepatotoxicity and nephrotoxicity of NPs
during their in vivo application.
Keywords gold, silver, nanoparticles, tryptophan-assisted
synthesis, hepatotoxicity, anticancer activity
1. Introduction
In recent years, the use of nanomaterials, particularly metal
nanoparticles (NPs), has expanded in biomedical research.
They are used in diagnosis and therapeutics due to their
unique properties, including small size, large surface area-
to-volume ratio, high reactivity to living cells, stability
under high temperatures, and translocation into the cells
[1]. Enormous scientific and technological interest has been
given to gold and silver NPs because of their easy synthesis,
chemical stability and unique properties. The intensive use
of nanotechnology in modern biological science, including
chemical sensing, biological imaging, drug delivery, cancer
treatment and considerable advances in their application
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[1, 2], do not reject the question of NP’s adverse effects in
relation to biological systems [3]. Due to their nanoscale
dimensions, they exhibit qualitatively new properties
which underlie their biological activity and possible toxic
effects. In spite of their extraordinary capacity for biocon‐
jugation with various molecules, there are studies showing
NPs to be cytotoxic due to their inherent physico-chemical
properties. Special attention should be paid to the potential
hepato-and nephrotoxic effects of NPs at the organism level
[4, 5], since the liver is the main homeostatic organ and is
the leading site of xenobiotic detoxication in the body. The
liver has the highest ability to accumulate NPs and is the
main target organ for NPs that are administered, which
greatly increases the risk of their toxic effects. A general
mechanism of nanomaterial toxicity is an induction of
oxidative stress in cells, where the molecular targets of
colloidal metal NPs are the lipid components of the plasma
and intracellular membranes and associated protein
complexes [6]. Nonspecific oxidative damage is one of the
greatest concerns limiting the implementation of NPs, and
the approaches aiming to attenuate this phenomenon
appear to be very important.
In this study, we estimated the potential in vivo toxicity of
colloidal Ag/Au NPs stabilized by sodium dodecyl sul‐
phate (SDS) and by the essential amino acid tryptophan
(Trp), with the specific aim of the possible improvement of
NPs biocompatibility using a natural compound as a
surface-bound stabilizing ligand. Finally, the anti-tumour
activity, as one of the possible application of NPs, was also
studied.
2. Experimental procedures
2.1 Synthesis and characterization of NPs
To obtain Ag/Au NPs, the following materials were used:
silver nitrate, tetrachlorauratic acid (AgNO3, HAuCl4,
Merck, Germany), sodium dodecyl sulphate (SDS, Sigma
Aldrich, Germany), sodium tetrahydroborate (NaBH4,
Fluka, Germany) and tryptophan (Trp, SC12-20120713,
China). Ag/Au NPs in a colloidal solution were obtained in
two ways. 1. The simultaneous chemical reduction of silver
nitrate and tetrachlorauratic acid in the presence of sodium
tetrahydroborate using as stabilizer surfactant SDS in a
molar ratio to the metal of 3:1. The concentrations in the
resulting solution used were C(M)=3 10-3M (С Ag=С Au=1,5
10-3 М), С(NaBH4)=9 10-3 М. 2. To reduce the toxicity of the
NPs, the simultaneous reduction of silver nitrate and
tetrachlorauratic acid using tryptophan as a reducing/
stabilizing agent was carried out. The components inter‐
acted in a molar ratio ν(M):ν(Trp)=1:2. The concentrations
in the resulting solution used were C(M)=10-3M (С Ag=С
Au=0,5 10-3 М) and C(Trp)=2∙10-3M. The molar ratio of Ag to
Au was 1:1 for both cases.
The absorption spectra of the colloidal solutions of Ag/Au
NPs were recorded in the UV-visible region with a spec‐
trophotometer, Lambda 35 (Perkin-Elmer, United States),
in 1 cm quartz cells. The particle size distribution function
was studied by a laser correlation spectrometer (LCS)
ZetaSizer-3 (Malvern Instruments, Worcestershire, United
Kingdom) equipped with a correlator Multi8 (computing
correlator type 7032 ce, Malvern Instruments, Worcester‐
shire, United Kingdom). The hydrodynamic diameter of
the NPs was calculated from the diffusion coefficient by the
Stokes-Einstein equation. 1 ml of studied suspension was
placed in a cylindrical optical glass cell with a diameter of
10 mm, which was located in a thermostated sample holder
of a laser correlation spectrometer. Registration and
statistical processing of the scattered laser light at 90° from
the suspension (helium-neon laser LGN–111 was used with
power output of 25 mW and wavelength of 633 nm) was
performed three times during 300 seconds. The resulting
autocorrelation function was treated with standard
computer programs PCS–Size mode v 1.61.
Electron microscopic images were obtained with a trans‐
mission electron microscope JEM–100C (JEOL, Japan) with
an accelerating voltage of 100 kV. For the calculation of
particle size distribution, the program ImageJ (National
Institutes of Health (NIH), United States) was used.
2.2 Animal husbandry and the NPs’ treatment
All the mice employed in our studies were congenic in the
C57BL/6J genetic background and were treated and
maintained according to the NIH Guide for the Care and
Use of Laboratory Animals [7]. The mice of either sex, aged
12 weeks and weighing 18-22 g, were used in the experi‐
ments. Every five mice of the same sex were housed in cages
containing a sterile paddy husk as bedding in a ventilated
animal facility with a controlled temperature (21 ± 2 0C). All
the mice were maintained on a laboratory complete diet
with free access to water. Forty mice of each sex were
randomly divided into five groups: one control group
(intact animals) and four experimental groups with
different NPs and vehicles respectively. The mice received
intra-peritoneal (i.p.) injections of approximately 100 μL of
the NPs solution (adjusting the final volume with the
animal weight for the given dose) at a dose of 500
μg/kg/day daily for 12 days. The corresponding groups
were administered with vehicle solutions (2∙10-3 M
tryptophan or 4,5∙10-3 M sodium dodecyl sulphate). Intact
animals of each sex (with no injections) were included as a
control group. The body weight of the animals and their
behaviour were carefully recorded, daily, during the course
of the experiment. One day after the last injection (day 13),
the mice were killed and the blood, liver, spleen, kidney,
lungs and brain were collected and weighted immediately.
Serum from the mouse blood was isolated by centrifuga‐
tion at 1,500 g for 10 min. The dissected tissues were frozen
in liquid N2 and stored continuously without thawing at
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-80 °C until analysis, and for the quantification of the gold/
silver content in each tissue.
2.3 Anti-tumour activity assessment
As a model of malignant tumour growth a Lewis lung
carcinoma was used. Tumour strain was kindly provided
from the National Bank of Cell Lines from Human and
Animal Tissues by R. E. Kavetsky Institute of Experimental
Pathology, Oncology and Radiobiology, NAS of Ukraine.
The transplantation was performed by intra-muscular
injection into a femoral muscle of 0.2 ml 10% cell suspen‐
sion in saline (3 × 106 cells/ml). Starting from day five after
tumour cell inoculation, the animals were divided into
groups receiving daily an intra-peritoneal suspension of
NPs (Ag/Au/SDS and Ag/Au/Trp) at the dose mentioned
above. The animal morphological parameters (animal
weight, primary tumour size) and survival rate were
monitored daily. Euthanasia of the animals (6-7 animals per
group) was performed on day 18 after Lewis carcinoma
transplantation under light ether anaesthesia. Following
sacrifice, the lungs were photographed and the number of
metastatic nodules was counted. Anti-tumour activity was
determined based on the parameters of tumour growth
inhibition, the survival rate and the rate of lung metastatic
infiltration.
2.4 Gold content determination in tissues
Analytical procedures for the determination of gold in
tissues were performed exactly as described by others [8].
Briefly, tissue samples were dried completely in a clean
oven at 60–70 °C. Each dried tissue was digested in an open
atmosphere to white ash using 30% hydrogen peroxide
(Merck, Germany) at 50–60 °C followed by digestion with
0.1 mL concentrated ultra-pure trace metal-free nitric acid
(Merck, Germany). The digested white ash was dissolved
in 0.25 M nitric acid. The recovery rate for elemental gold
after the sample preparation determined by the standard
additions method was more than 90%. The concentration
of gold was measured in the samples using atomic absorp‐
tion spectrophotometer S-115М1-PC (Ukraine), equipped
by the microelement automatic calculation software
LAB_AAS (Selmi, Ukraine). Each digested sample was
further diluted suitably (1:2 – 1:50 v/v, depending on the
tissue type and amount) using 0.25 M ultra-pure nitric acid
prior to analysis. Sample atomization was performed in a
flame of acetylene:air mixture. The lamp was operated at a
specific absorption line of gold at 242.8 nm; a deuterium
lamp was used for background correction. The elemental
gold standard was used for all calibration curves.
2.5 Liver and kidney function tests
Alanine aminotransferase (ALT, EC 2.6.1.2) and gamma-
glutamyl transpeptidase (GGT, EC 2.3.2.2) enzymatic
activities were determined in mouse serum to assess liver
injury using a colorimetric kit from Felisit Diagnostics
(Ukraine), according to the manufacturer’s protocols.
Blood creatinine and urea levels were determined to assess
renal filtration using an enzymatic kit from Felisit Diag‐
nostics (Ukraine), according to the manufacturer’s proto‐
cols.
2.6 Oxidative damage measurement
The oxidative modification of hepatic proteins was deter‐
mined by the assessment of both the level of protein
carbonylation, as described by others [9], and the level of
protein sulfhydryl groups [10]. The measurement of
protein carbonyls was performed spectrophotometrically
(λ=370 nm) following their covalent reaction with 2,4-
dinitrophenylhydrazine with the formation of a stable 2,4-
dinitrophenyl hydrazone product. The detection of protein
sulfhydryl groups involved specific reaction with Ellman's
reagent (5,5'-dithiobis (2-nitrobenzoic acid, DTNB) with a
subsequent absorbance reading at 412 nm. Lipid peroxida‐
tion in the liver was determined spectrophotometrically
(λ=532 nm) by assessing the level of thiobarbituric acid-
reactive substances (TBRAS), as described by others [11].
2.7 Statistical analysis
All the data are presented as means ± SD. Statistical
comparisons were first analysed by a one-way ANOVA
followed by multiple comparisons employing Tukey’s
HSD post hoc test. P-values of <0.05 were considered
statistically significant.
3. Results and discussion
For the successful application of nanomaterials in bio‐
science, it is important to understand the biological fate and
potential toxicity of NPs. Despite the widespread use of
nano-sized gold and silver, relatively few studies have been
undertaken to determine the cytotoxic effects of Ag and Au
NPs exposure. Several methodological approaches have
been proposed to be used in the reduction of NP toxicity,
including their conjugation and functionalization [1]. In the
current work, we developed bimetallic gold and silver NPs
for biomedical application which were potentially less toxic
than Ag/Au/SDS in relation to a mouse model system based
on clinical biochemical parameters and oxidative damage
products estimation. The bimetallic Ag/Au composition of
the studied NPs was selected based on our previous studies
[12]. The NPs structure, electronic and optical properties,
chemical stability and their activity in various biological
processes differ greatly compared to the properties inher‐
ent to the individual metals [1]. The transition from
monometallic to bimetallic NPs is accompanied with the
change of the surface plasmon absorption energy com‐
pared to the components of the bimetallic compositions. As
such, we can combine the benefits of both gold and silver
in one bimetallic NP. The mentioned characteristics are
largely dependent on the method of synthesis and the ratio
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of components. In this study, we applied an essential amino
acid tryptophan that can simultaneously act as a reducing
and stabilizing agent of gold, and which has the ability to
reduce the toxic effect of NPs on living cells (besides, it is
easy to observe spectrally).
3.1 Characterization of NPs
The formation of particles is confirmed by the appearance
of the characteristic colour of Ag/Au NPs solutions and



















Figure 1. The absorption spectra of bimetallic NPs in solution. 
Line 1 corresponds to Ag/Au/SDS and line 2 to Ag/Au/Trp 
(dilution to metal concentration 10-4M).  
 
The SPR maximum at 427 nm (Fig. 1) is typical for 
Ag/Au/SDS alloy NPs and has an intermediate position 
between the maxima of monometallic Ag and Au NPs at 
400 and 520 nm, respectively. 
The SPR maximum of AgAu/Trp is shifted to longer 
wavelengths (578 nm) compared to the absorption 
maximum of monometallic Au/Trp NPs (560 nm) and 
indicates the formation of large aggregates in the system. 
According to the data obtained with a laser correlation 
spectrometer (LCS) in the case of the simultaneous 
reduction of metals in two specified systems, the particles 
of different sizes were generated (Fig. 2). For the 
Ag/Au/SDS system, where the strong reductant as sodium 
tetrahydroborate is used and where there is a competition 
of nucleation and growth of nuclei processes with the 
domination of the first process over the second one, the 
particles of 8-12 nm are mainly formed. In the case of a 
weak reducing agent – the amino acid tryptophan – the 
possibility of multi-electron interactions between the 
components occurs due to the formation of charge transfer 
complexes between the tryptophan donor groups and the 
gold ions/NPs. As such, the reduction process significantly 
slows down, leading to the growth of large particles with 
an average size of 370-450 nm (Fig. 2B.). However, such a 
large size of several hundred nanometres is related not to 
the actual size of Ag/Au/Trp NPs but to their aggregates 
in a polymeric matrix arising from the oxidative 
polymerization of indole groups of tryptophan during 
reduction/stabilization. This is confirmed by the TEM 
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Figure 2. The size distribution of particles in colloids by volume and number according to LCS data (A., B.): Ag/Au/SDS (1) and Ag/Au/Trp (2). TEM image
and size distribution of particles in Ag/Au/Trp colloids (C.)
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The large aggregates observed consist of a plurality of
smaller particles, mainly about 5-15 nm, and a small
number of particles of 50-70 nm. Thus, for both Ag/Au/SDS
and Ag/Au/Trp systems in colloids, irrespective to the type
and strength of the reducing agent, the NP with an average
size of around 10 nm are formed.
3.2 Tryptophan-assisted synthesis reduces gold/silver NP
potential hepato-and nephrotoxicity
In the present study, we explored the relationship of NP
synthesis with their hepato-and nephrotoxicity in vivo. The
NPs employed in this study had an average size of 10 nm
(Fig. 1, Fig 2). The mice were treated with bimetallic Ag/
AuNPs, prepared with a different stabilizing agent, by
intra-peritoneal injection in the dose of 500 μg/kg/day for
12 days and daily examined for any changes in the mor‐
phology and behaviour. All the treated male and female
mice survived throughout the experimental period without
exhibiting any abnormalities. The mice did not show any
pronounced symptoms of toxicity, such as weight loss,
changes in food consumption or water intake, or changes
in fur colour. The visual examination of NP-treated organs
did not show any significant morphological changes in
comparison to the control. The values of the visceral organ
(liver, kidney, spleen) weights did not differ in either the
male or female mice among the experimental and control
groups (data not shown).
More information was retrieved from biochemical param‐
eters reflecting the functional state of the liver and kidneys.
These parameters revealed the hidden NP toxicity, espe‐
cially for those obtained using SDS as a stabilizer. ALT and
GGT activities showed slight but significant elevation for
both sexes under Ag/Au/SDS NP administration (Fig. 3A
and 3B). The increased serum ALT and GGT activities were
noted for both SDS and Ag/Au/SDS-treated groups,
suggesting that the observed effect was instead caused by
the stabilizer used in the synthesis rather than the metal
component by itself. The most pronounced effect was
observed in serum ALT activity in males, suggesting their
greater susceptibility to the hepatotoxicity of Ag/Au/SDS
NPs. This hepatotoxic effect was not observed for mice after
Ag/Au/Trp administration (Fig. 3A and 3B).
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Figure 3. Liver injury and renal filtration capacity in mice after the daily intra-peritoneal administration of NPs (Ag/Au/SDS and 
Ag/Au/Trp) at a dose of 500 μg/kg/day for 12 days. Serum alanine aminotransferase (Panel A) and gamma-glutamyl transpeptidase 
activities (Panel B) in mice after NP administration. Blood creatinine (Panel C) and urea (Panel D) levels in mice after NP administration. All 
the values are given as the mean ± 1 S.D., n = 7 for each group. Values marked with different letters (a, b, c) are statistically different, P < 
Figure 3. Liver injury and renal filtration capacity in mice after the daily intra-peritoneal administration of NPs (Ag/Au/SDS and Ag/Au/Trp) at a dose of 500
μg/kg/day for 12 days. Serum alanine aminotransferase (Panel A) and gamma-glutamyl transpeptidase activities (Panel B) in mice after NP administration.
Blood creatinine (Panel C) and urea (Panel D) levels in mice after NP admi istration. All the values are given as the ean ± 1 S.D., n=7 for each group. Values
marked with different letters (a, b, c) are statistically d fferent, P < 0.05
The level of blood creatinine and urea symptomatic of the
renal functions was also increased compared to the intact
animals. However, the significant changes in values
reflecting renal filtration capacity were observed only in
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groups of animals of both sexes treated with Ag/Au/SDS
NPs. There were no significant changes in the blood
creatinine and urea levels for mice treated with tryptophan-
stabilized Ag/Au NPs in comparison to either tryptophan-
treated or intact animals (Fig. 3C and 3D).
The method used in the current work involved tryptophan
as a reducing/stabilizing agent, allowing the obtaining of
NPs about the same size as those involving SDS. Thus, the
type of stabilizing agent we consider to be a main feature
underlying the observed reduction of the hepato-and
nephrotoxicity of Ag/Au/Trp. Several studies confirmed
the importance and the great influence of NP size on their
biodistribution and interaction with complex, in vivo,
whole-animal biological systems, where NPs of small sizes
(with associated ultrahigh activity) were shown to interact
with local tissues and provoke dysfunctions of the organs
[13, 14]. The dependence on the size, shape and the
possibility of internalization with corresponding cytologi‐
cal effects were shown for the functionalized gold NPs [15,
16]. An additional and often key factor that may influence
the toxicity of NPs is the chemicals (or “initial reagents”)
used during the synthesis; thus, in considering NPs as a
multi-component system the surface capping agents
should be taken into account as permanent components of
this system.
The origin of NPs’ cytotoxicity from the surfactant/
stabilizer used was already shown for Au NPs stabilized
with cetyltrimethylammonium bromide [3, 17]. Thus,
applying the protective agent that replaces potentially
cytotoxic SDS [18] during the preparation of NPs may
result in the observed lower in vivo toxicity.
Thus, in the present study an approach involving trypto‐
phan as a stabilizer during Ag/Au NPs synthesis was used
aiming to reduce the toxicity observed in mice. The
performed biochemical studies revealed that liver and
kidneys are target organs for the administered NPs, raising
the possibility of their potential hepato-and nephrotoxicity.
These were further demonstrated by the measurements of
blood biochemical indexes (ALT, GGT, creatinine, urea),
reflecting the renal and hepatic functions of the experimen‐
tal mice. During the administration of Ag/Au tryptophan-
stabilized NPs, the studied parameters did not differ from
the intact animals, in contrast to that observed in mice
continuously administered with NPs obtained by the
classical protocol involving SDS, where an elevation in the
serum ALT, GGT, creatinine and urea levels suggested the
presence of marked hepatic and renal damage after
continuous NP administration.
3.3 Tryptophan-assisted synthesis affects gold/silver NP
biodistribution in vivo
The distribution of the administered NPs was detected
based on the gold element accumulation in diverse organs
such as the liver, spleen, kidneys, lungs, brain and heart.
The NPs were distributed in all the organs, with the highest
accumulation in the spleen, followed by the liver, lungs,
heart, kidneys and brain (Fig. 4). It is known that nanoscale
particles as any inorganic compound are captured by the
cells of the reticuloendothelial system (RES); therefore, they
are predominantly accumulated in the spleen and liver in
relatively high concentrations [19]. There were no signifi‐
cant differences in the Ag/Au/SDS NPs’ accumulation in
different-sex animals, except for the kidneys, where the
level of the gold element was observed twice as much in
males compared to females. Using tryptophan for the
stabilization of the NPs affected their biodistribution
within the body, reflected in the changes of the gold
element level in the liver, kidneys and heart. There was a
statistically significant increase in the gold concentration of
hepatic tissue samples from the groups exposed to Ag/Au/
Trp NPs in this study. The difference observed for the liver,
where there was an almost three-fold increase in the
accumulation of Ag/Au/Trp NPs compared to Ag/Au/SDS,
may be explained by the fact that the liver is considered as
a target organ for silver and gold NPs, which are taken up
by the cells of RES [5, 14]. Being captured, the NPs were
observed as being located in the cytoplasmic vesicles and
lysosomes of liver-resident macrophages – namely,
Kupffer cells [19].
In addition, the lower level of gold in the heart of males and
females (for 45% and 25% respectively) was noted in
groups receiving Ag/Au/Trp NPs compared to SDS-
stabilized colloids. An opposite tendency was observed in
the tryptophan-stabilized NP distribution in the kidneys of
mice, where the amount of gold determined in the male
kidney was significantly lower (although higher in the
female kidney) compared to the sex groups treated with
Ag/Au/SDS (Fig. 4), indicating a marked gender-depend‐
ent distribution of this NP type with respect to the kidneys.
Our results are consistent with the published data on NP
distribution in animals of different sexes [20, 21].
3.4 Tryptophan-stabilized Ag/Au NPs exhibit lower pro-oxidant
activity in relation to cellular lipids, but do not differ from the
SDS-stabilized NPs in their ability to induce protein oxidation
The penetrating of NPs into the cell through endocytosis
can disrupt the integrity of plasma and/or intracellular
membranes [17], leading to cell death in high local concen‐
trations. Earlier reports have emphasized the role played
by oxidative stress in NP toxicity [22-25]. Oxidative stress
has specific effects in the cells, including oxidative damage
to lipids and proteins.
The performed analysis showed a significant increase in
thiobarbituric acid reactive substances’ formation in the
visceral organs of animals treated with Ag/Au/SDS NPs.
(Table 1.).







males females males females males females
Liver
Intact 27,77±3,50a 29,31±3,24a 0,27±0,06a 0,27±0,09a 13,65±1,88a 13,22±1,82a
Ag/Au/SDS 74,95±17,96b 74,66±18,20b 0,97±0,22b 1,16±0,34b 4,39±1,78b 4,19±1,17b
Ag/Au/Trp 39,36±9,81a 28,81±15,34a 0,76±0,15b 0,69±0,22b 9,03±3,70c 9,01±2,33c
Kidney
Intact 38,29±2,90a 38,70±3,46a 0,45±0,10a 0,45±0,08a 7,34±0,90a 7,20±1,64a
Ag/Au/SDS 81,91±21,77b 33,59±15,41a 0,97±0,26b 1,15±0,35b 4,39±1,23b 4,16±2,64b
Ag/Au/Trp 34,57±12,79a 79,33±23,42b 0,83±0,21b 0,83±0,17b 5,56±1,97a,b 5,11±1,88a,b
Spleen
Intact 20,91±2,20a 29,13±2,86b 0,40±0,05a 0,39±0,07a 8,53±0,91a 8,24±1,32a
Ag/Au/SDS 97,64±18,06c 66,85±14,88c 0,67±0,07b 0,87±0,13b 5,78±2,45b 5,49±2,12b
Ag/Au/Trp 30,75±11,43b 27,68±13,95b 0,61±0,13b 0,49±0,17c 5,37±2,41b 5,73±2,52b
Table 1. Oxidative damage products in mouse liver, kidneys and spleen after daily intra-peritoneal administration of NPs (Ag/Au/SDS and Ag/Au/Trp) at a
dose of 500 μg/kg/day for 12 days. All values are given as the mean ± 1 S.D., n=6 for each group. Values marked with different letters (a, b, c) are statistically
different, P < 0.05
The intra-peritoneal administration of NPs during 12 days
in daily doses of 500 μg/kg/day led to the development of
enhanced lipid peroxidation as evidenced by an increase of
TBARS by 2.7 in the liver, 2.1 in the kidneys and almost 4.5
in the spleen (Table 1.). However, such prominent features
of lipid peroxidation were not observed in the liver of
Ag/Au/Trp NP-administered animals. The values of the
hepatic TBARS level in these groups did not exceed the
parameters of the intact mice of both sexes. A significant
increase in the TBARS was found in female kidneys after
the Ag/Au/Trp NPs’ treatment, reflecting the tendency
observed for the accumulation of this NP type in mouse
kidneys. The female mice exhibited near-normal levels of
lipid peroxidation products in the kidney when adminis‐
tered with SDS-stabilized NPs; however, in males this was
observed during tryptophan-stabilized NPs treatment. The
analysis of the accumulation of protein oxidative modifi‐
cations (i.e., carbonyl derivatives and the level of sulfhydryl
groups) showed that the NPs used, irrespective to the
stabilizer used, are able to cause oxidative degradation of
the cellular proteins (Table 1.). Moreover, the relative
values of the carbonyl derivatives’ accumulation observed
in the liver, kidneys and spleen showed higher pro-oxidant
activity for the SDS-stabilized NPs. Presumably, during the
penetration of NPs into the cell, the loss of the surface-
associated stabilizer occurs and its role in the reduction of
the pro-oxidant activity is neglected. This may explain the
same accumulation values of the protein oxidation prod‐
ucts regardless of the type of stabilizer used.
3.5 Tryptophan-stabilized Ag/Au NPs possess anti-tumour
activity
The studies showed that the daily intra-peritoneal admin‐
istration of a bimetallic nanocomposite at a dose of 500 μg/
kg led to the inhibition of the growth of the Lewis lung
carcinoma primary tumour from day 16 of the experiment
(day 11 of NP administration). However, the likely positive
result was detected only in the group of animals with a
carcinoma treated with Ag/Au/Trp (Fig. 5B). On the 21st day
of the experiment, the rate of tumour growth inhibition (by
weight) was 41% in this group compared to 15% in the
group receiving Ag/Au/SDS, while the observed decrease
in the size was 34% for Ag/Au/Trp-treated animals and
only 11% for animals treated with Ag/Au/SDS. On the
25th day of the experiment, the inhibition of the growth of
the Lewis carcinoma primary tumour accounted for 61%
compared to 30% in the animals injected with Ag/Au/SDS
(Fig. 5B,5C, 5D) after 20 days of Ag/Au/Trp administration.
Along with less anti-tumour activity, the Ag/Au/SDS
nanocomposite had higher toxicity (Fig. 5A). This was
evidenced by higher levels of mortality in animals receiv‐
ing a daily dose of 500 μg/kg of this nanocomposite. In
particular, after a seven day period of the administration of
NPs, the mortality rate was 35%, reaching 50% on day 14
of administration (day 21 of the experiment) and was 85%
at the terminal stages of observation. However, in the
Ag/Au/Trp-treated group, the level of mortality did not
exceed 40% throughout the experimental period (Fig. 5A).
During the administration of the bimetallic nanocomposite,
the frequency of lung metastasis did not differ among the
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groups, and was 100%. However, after two weeks of NP
injections at a dose of 500 μg/kg, the metastasis inhibition
index was 26% for the Ag/Au/SDS-treated mice and 43%
for the Ag/Au/Trp (Fig. 5E). The severity assessment of the
of metastatic process revealed that the use of the studied
NPs led to less than the second degree of metastatic lesion
(number of metastasis from 10 to 30, some of them sized
more than 1 mm), while in 45% of the control group the
animals’ high metastatic potential was observed (over 30
metastasis, or the presence of continuous drain nodes) (Fig.
5F). The differences in the number of metastases and their
diameter in the group Ag/Au/SDS were not statistically
significant and had the character of a trend, while after the
administration of bimetallic Ag/Au/Trp NPs the average
diameter of the metastasis at 21 days was statistically
significantly lower compared with the control group (Fig.
5E). Only metastases with a small diameter were identified
in the lungs of the Ag/Au/Trp-treated animals; moreover,
the number of metastases was also much lower than in

























































































































































































































































































Figure 4. Gold element level in body tissues. The values correspond to the gold concentration relative to the weight of the 
dry tissue. All values are given as the mean ± 1 S.D., n = 7 for each group and genotype. Values marked with different letters 
(a, b, c) are statistically different, P < 0.05. 




              
 
 
Figure 5. Anti-tumour activity of NPs. Survival rate (Panel A) and primary tumour size (сm3) (Panel B) in mice of 
experimental and control groups at different experimental periods during Lewis lung carcinoma growth; primary tumour 
size (сm3) (Panel C) and mass (g) (Panel D) on day 18 of Lewis lung carcinoma growth; metastasis average diameter (mm) 
Figure 4. Gold element level in body tissues. The values correspond to the gold concentration relative to the weight of the dry tissue. All values are given as
the mean ± 1 S.D., n=7 for each group and genotype. Values marked with different letters (a, b, c) are statistically different, P < 0.05
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Figure 5. Anti-tumour activity of NPs. Survival rate (Panel A) and primary tumour size (сm3) (Panel B) in mice of experimental and control groups at different
experimental periods during Lewis lung carcinoma growth; primary tumour size (сm3) (Panel C) and mass (g) (Panel D) on day 18 of Lewis lung carcinoma
growth; metastasis average diameter (mm) (Panel E) and representative photograph (Panel F) in lungs at day 18 of Lewis lung carcinoma growth. All values
are given as the mean ± 1 S.D., n=7 for each group and genotype. Values marked with different letters (a, b) are statistically different, P < 0.05
In summary the data generated from the present study
supports the fact that the use of tryptophan in NP synthesis
is effective in attenuating the potential hepatotoxicity and
nephrotoxicity of NPs during their in vivo application.
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